Biotech Co.* |
Pharma Co. |
Type/Product Area |
Terms/Details (Date) |
4SC AG |
Schwarz Pharma AG (Germany) |
They entered a research deal focused on the central nervous system |
Terms were not disclosed; the news came concurrent to their ending a deal in the area of urology (12/12) |
Ablynx NV* |
Boehringer Ingelheim GmbH (Germany) |
Deal to develop therapies for Alzheimer's disease using Ablynx's Nanobodies' technology |
They also will conduct joint research; Ablynx said the deal could be worth up to nearly $65M in an up-front fee, as well as development and commercial milestones; it also would get royalties on sales (1/8) |
Acadia |
Ipsen SA (France) |
Acadia licensed certain technology designed to add to its serotonin platform |
The nonexclusive license complements Acadia's existing program; Ipsen gets $0.25M up front, along with potential milestone and royalty payments (12/4) |
Acumen |
Merck & Co. Inc. |
Merck got exclusive rights to research and develop amyloid-derived diffusible ligand-directed diagnostics |
The license represented an amendment to a Alzheimer's disease-focused deal begun in 2004; other details of that deal remained unchanged (11/27) |
Advinus |
Merck & Co. Inc. |
Collaboration to develop drug candidates for treating metabolic disorders, starting with two target programs |
Advinus gets an up-front payment and milestone payments of up to $74.5M per target; it also would get royalties on any resulting sales (11/16) |
Affectis |
Palau Pharma SA(Spain) |
Licensing deal for the global rights in all central nervous system indications to a clinical stage cyclooxygenase-2 inhibitor |
Terms were not disclosed, but the deal includes an up-front payment, milestones and royalties (1/24)** |
Affymetrix |
Sysmex Corp. (Japan) |
Deal to develop and market in vitro diagnostic tests; also, Sysmex got nonexclusive rights to use microarray technology |
Sysmex got exclusive rights to distribute Affymetrix microarray products and instrumentation in Japan, and potentially in other Asia-pacific countries; terms were not disclosed (12/13) |
Albany |
Bristol-Myers Squibb Co. |
Two-year deal for AMRI to use its natural products technologies for drug discovery against BMS target |
AMRI gets an up-front payment and research funding, along with potential milestone and royalty payments (12/21) |
Alfacell |
Genesis Pharma SA (Greece) |
Genesis got rights to the cancer drug Onconase in Greece and seven other countries in southeast Europe |
Terms of the exclusive license deal were not disclosed (12/20) |
Altea |
Undisclosed pharmaceutical companies |
Research agreements under which Altea will apply its PassPort System transdermal delivery technology to injectable drugs to assess the feasibility of delivering them through a skin patch |
The companies have an option to enter into broader licensing agreements for development and commercialization (1/18) |
Ambrilia |
Teva Europe |
Teva got certain distribution rights to a sustained-release formulation of octreotide for treating acromegaly |
Teva got rights in France, Germany, Benelux, Spain and Scandinavia; Ambrilia is entitled to milestone payments, supply payments and royalties on sales (11/15) |
Applied |
Eli Lilly and Co. |
Deal to develop therapeutics for treating Alzheimer's disease; Lilly gets rights to resulting compounds |
APNS gets $1.5M up front and an equity investment of $0.5M, plus R&D support; it could get up to $20M in milestone payments per compound, and royalties on resulting sales (11/28) |
Archemix |
Merck KGaA (Germany) |
Multiyear, mutlitarget agreement to discover and develop new aptamer-based treatments for cancer |
Archemix will receive up to $10M in an upfront payment and research funding, plus milestones and royalties; it also has co- promotion rights (1/17) |
Archemix |
Pfizer Inc. |
Deal to develop aptamers as therapeutics against three disease-associated targets identified by Pfizer |
Archemix gets an up-front payment and research funding, as well as potential development milestones and royalties on sales (1/9) |
Ardea |
Valeant Pharmaceuticals International Inc. |
Ardea acquired three discovery programs, two in HIV and one in cancer and inflammation; separately, it will work to advance a preclinical neuropharmacologyprogram for Valeant |
Valeant is entitled to milestonepaymentsof $17M to $25M for each of three programs, and mid- single-digit royalties on resulting sales; Valeant could regain rights to the lead HIV program in exchange for $10M, plus milestones and royalties; Ardea gets $3.5M per year in the research deal (12/22) |
Argenta |
AstraZeneca plc (UK) |
A $500M deal to identify improved bronchodilators to treat chronic obstructive pulmonary disease |
Argenta will get $21M up front, plus committed research funding and preclinical milestone payments (1/31) |
Artemis |
Merck & Co. Inc. |
Artemis will generate genetically engineered shRNAi knockdown mouse models for Merck |
Merck will use the models for in vivo functional analysis of certain disease-related genes; terms of the deal were not disclosed (11/20) |
AVEO |
Kirin Brewery Co. Ltd. (Japan) |
AVEO got rights to KRN951, a once-a-day, oral VEGF receptor inhibitor |
The anticancer agent is in Phase I trials; the rights are exclusive outside Asia; terms of the deal were not disclosed (1/4) |
Avexa Ltd. |
Shire plc (UK) |
Agreement for the North American rights to SPD754, an investigational HIV com- pound also known as apricitabine |
Avexa paid $10M up-front for the rights and Shire is entitled to milestones and royaties, plus 8M additional Avexa shares; SPD754 is in Phase IIb trials (1/23) |
BaroFold |
Pfizer Inc. |
Pfizer got rights to use BaroFold's technology for refolding and producing proteins |
Terms of the multisite research license were not disclosed (1/9) |
Basilea |
Cilag GmbH International (affiliate of Johnson & Johnson) |
Basilea exercised its co-promotion option on ceftobiprole in North America and Europe |
The anti-MRSA cephalosporin antibiotic is in Phase III trials (12/7) |
Biocortech |
Servier (France) |
Deal to discover and develop drugs for treating central nervous system disorders |
Servier has worldwide rights to resulting products; terms of the deal were not disclosed (12/4) |
Biota |
Boehringer Ingelheim GmbH (Germany) |
Deal to develop and market Biota's nucleoside analogues in development for treating hepatitis C virus and potentially other diseases |
Biota gets a technology access fee and research support; it could get up to $102M in clinical and sales milestones, as well as royalties on resulting sales (11/27) |
BioTie |
H. Lundbeck A/S (Denmark) |
Lundbeck got certain rights to nalmefene for treating substance abuse disorders and impulse control disorders |
Rights are worldwide excluding North America, the UK, Ireland, Turkey, and South Korea; BioTie gets €10M up front and up to 78M more in milestone payments, plus royalties on any resulting sales (11/27) |
BioTie |
F. Hoffmann-La Roche Ltd.(Switzerland) |
Roche got an option to BioTie's antibody program targeting vascular adhesion protein-1 in inflammatory diseases |
Roche already held options to BioTie's VAP-1 SSAO enzyme small-molecule inhibitor candidates; Roche is paying €5M for an option to the antibody program through Phase Itrials (11/24) |
BioVeris |
Baxter Healthcare Corp. |
BioVeris got nonexclusive rights to use Neisseria meningitidis group C, Neisseria meningitidis group Y and Haemophilus influenzae type b components for use in new vaccine candidates |
Rights cover use as part of vaccine candidates for preventing meningitis and sepsis; Baxter gets an up-front fee along with potential milestone and royalty payments (12/26); rights to Neisseria meningitidis group Y andHaemophilus a license fee, milestone payments, sales royalties and other fees (1/26) |
Cambridge |
Panacea Biotec Ltd. (India) |
They formed a joint venture for development of various combination vaccine products |
Panacea gained a 10% stake in CBL through a £1.95M investment; it licensed CBL's stable liquid technology for use in development of various vaccines (12/6) |
Catalyst |
Wyeth Pharmaceuticals |
Catalyst will direct its engineered human proteases technology to two targets for Wyeth, one in metabolic disease and one in oncology |
Payments to Catalyst from the two deals could total up to $100M in up-front license fees and milestone and R&D payments; Catalyst also would get royalties on any resulting sales (1/8) |
Cell Signaling |
AstraZeneca plc (UK) |
CST will develop rabbit monoclonal antibodies to AstraZeneca oncology targets |
CST will validate antibodies and immunoassays for monitoring target and small- molecule activity; terms were not disclosed (12/19) |
Ciphergen |
Quest Diagnostics Inc. |
Quest will help Ciphergen develop a blood- ased assay for the detection of peripheral artery disease |
The deal marked the second development plan under an existing collaboration; they already are developing an ovarian tumor triage test; terms were not disclosed (1/3) |
Cobra |
Cequent Pharmaceuticals Inc. |
Agreement to develop a treatment for an inherited form of bowel tumor, familial adenomatous polyposis |
The treatment will combine Cobra's ORT technology for creating stable, genetically engineered strains of microorganisms without the use of antibiotics or antibiotic gene, with Cequent's TransKingdom RNA interference technology (1/24)** |
Compute Ltd.* |
TeaPharmaceutical Industries |
Agreement to discover biomarkers for the detection of drug toxicity in preclinical stages of drug development |
Compugen granted Teva a license to use the discovered biomarkers for research and development while retaining commercialization rights for licensing to other companies and for internal use (1/30) |
Crucell NV |
Merck & Co. Inc. |
They entered a cross-licensing deal coveringvaccine technologies |
Merck got rights to use Crucell technology in an additional vaccine field, and Crucell got access to large-scale manufacturing technology from Merck (12/27) |
Crucell NV |
Novo Nordisk (Denmark) |
Non-exclusive research license agreement to allow Novo to use Crucell's STAR technology for the production of monoclonal antibodies |
Novo intends to evaluate the technology using its mammalian CHO cell line along with its antibodies in return for a license issuance fee, a success-based fee and annual maintenance fees provided the license is extended upon evaluation (1/16) |
Cubist |
AstraZeneca plc (UK) |
AstraZeneca got rights to Cubicin in China and certain other countries in Asia, the Middle East and Africa not already licensed |
The deal on the antibiotic does not include the unpartnered Japan; Cubist gets $10.25M up-front and supply payments, as well as potential regulatory and sales milestones (12/4) |
CureMark |
Balchem Corp. |
CureMark got rights to use PharmaShure drug delivery technology in its digestive/pancreatic enzyme products |
A focus of CureMark's effort is autism; its rights in that area are exclusive; terms of the deal were not disclosed (11/15) |
CXR |
Rosetta Biosoftware (unit of Merck & Co. Inc.) |
CXR licensed the Rosetta Resolver system to investigate mechanisms of drug toxicity |
CXR will use the technology for toxicological profiles of early stage compounds; terms of the deal were not disclosed (11/20) |
Digilab Inc.* |
Abbott Molecular Inc. |
Abbott exercised its option to evaluate candidate biomarkers for lung cancer |
Abbott has an option to acquire exclusive licenses to biomarkers identified by Digilab, which would get royalties on sales (12/21) |
DOR |
Sigma-Tau Pharmaceuticals Inc. |
Sigma-Tau got rights through February to negotiate an alliance on orBec and potentially other DOR products |
DOR gets a $1M equity investment in exchange for 4M shares, and a $2M advance payment in cash; orBec is being developed for treating gastrointestinal manifestation of graft-vs.-host disease (1/4) |
Durect |
Nycomed A/S (Denmark) |
Deal to develop Durect's Posidur post- perative pain relief depot product; Nycomed got rights in Europe; Durect has rights in America and Asia |
Durect gets $14M up front, and up to $188M in development and sales milestones; it would get royalties of 15% to 40%; they will equally fund development (11/29) |
Elusys |
Pfizer Inc. |
Deal to develop therapeutics for infectious diseases using Elusys' HP Antibody technology; the deal includes Elusys' ETI-211 |
Elusys gets an up-front equity investment, R&D funding and potential research mile- stones; it would be entitled to further mile- stone and royalty payments if Pfizer options rights to resulting products (1/4) |
Enanta |
Abbott Laboratories Inc. |
Deal to develop hepatitis C virus NS3 and NS3/4A protease inhibitors from Enanta |
Enanta gets an up-front fee and equity investment totaling $57M; it could get up to $250M more in milestone payments, as well as double-digit royalties; it kept a 40% funding and profit option in the U.S. (12/12) |
Entelos Inc. |
Johnson & Johnson Pharmaceutical Research & Development LLC |
Entelos got an option to exclusively license certain progesterone-receptor modulators for a range of indications |
Entelos is providing biosimulation services to J&JPRD, compensated in part through the grant of this option; terms of the deal were not disclosed (1/11) |
EPIX |
GlaxoSmithKline plc (UK) |
Multitarget deal to discover, develop and market drugs targeting four GPCRs for treating various diseases as double-digit royalties on sales (12/12) |
EPIX gets $35M up front, half from an equity investment in exchange for 3M shares; EPIX also could get up to $1.2B in milestone payments across the four programs, as well |
Evotec AG |
Solvay Pharmaceuticals (UK) |
Two contracts: one for fragment-based drug discovery; the other to extend an existing library synthesis contract for another 12 months |
Solvay will access Evotec's fragment- based screening platform and fragment library to identify fragment hits against a high-priority target; Solvay will pay an access fee; this is the third time in six years it has extended the library synthesis contract (1/22) |
Exelixis Inc. |
Bristol-Myers Squibb Co. |
Exelixis will lead effort to discover targeted therapies for treating cancer; BMS would lead development |
Exelixis gets $60M up front, and would get $20M for each of three candidates chosen by BMS; Exelixis has an option to share costs and profits in the U.S., or be entitled to milestone and royalty payments (12/18) |
FivePrime |
Centocor Inc. (unit of Johnson & Johnson) |
FivePrime will screen its protein library in a deal to discover proteins and targets against osteoarthritis and pulmonary fibrosis |
FivePrime gets cash and an equity invest- ment of $15M up front, and two years of funding; it also is eligible to receive milestone and royalty payments on resulting products (1/3) |
Fovea |
Novartis Pharma (Switzerland) |
Exclusive development and commercialization agreement for RdCVF (rod-derived cone viability factor) for retinal degenerations |
Fovea will fund and conduct preclinical and clinical development of RdCVF up to commercialization; Novartis would be entitled to development and regulatory milestones, plus royalties (1/16) |
Genfit (France; |
Merck KGaA (Germany) |
Three-year project with Merck to validate a new therapeutic class to treat diabetes and insulin resistance; two-and- -half year program in cardiometabolic diseases, aimed at identifying new ligands in orphan nuclear receptors from a bank of natural products |
Agreements give Genfit funding of €2.2M toward its research activities (1/31)** |
GeneMedix |
Reliance Life Sciences Pvt. Ltd. (India) |
Reliance plans to invest £14.6M ($28.6M) in GeneMedix, giving it 74% of the company |
The investment could increase to £32.1M over five years; RLS, an affiliate of the Reliance Group, intends to keep GeneMedix a public company (12/20) |
Genizon |
Pfizer Inc. |
License and collaboration deal to provide diagnostic rights to Genizon's discovery programs in Alzheimer's disease, attention deficit hyperactivity disorder and endometriosis |
Genizon retains therapeutic rights; Pfizer agreed to pay up-front license fees, funding for research on genetic variations associated with diseases and also will purchase an equity stake in Genizon (1/16) |
Genmab A/S |
GlaxoSmithKline plc (UK) |
Worldwide license deal covering Genmab's HuMax- CD20 antibody, which is in late- tage trials for blood cancers and rheumatoid arthritis |
Genmab gets a $102M license fee up front, and an equity investment of $357M for 4.47M shares; about $1.6B could be earned in development and commercial milestones; Genmab would get double-digit royalties on sales; and also has certain co- promotion rights in the U.S. and Nordic countries (12/19) |
Graffinity |
Boehringer Ingelheim Pharmaceuticals screened by Graffinity Inc. |
BI exercised options under their original deal that will increase the number of targets |
Graffinity will receive additional technology access fees under the new deal; terms were not disclosed (12/13) |
Halozyme |
F. Hoffmann- La Roche Ltd. (Switzerland) |
Deal to apply Halozyme's Enhanze delivery technology to Roche's biological therapeutic compounds; it is based on rHuPH20,a recombinant human hyaluronidase |
Halozyme get $20M up front and an $11M equity investment, about 5% of the firm; Roche initially gets rights for three targets, and an option to 10 more over 10 years; milestones could total $111M on the first three, plus royalties; each additional target could result in milestones of $47M (12/5) |
HUYA |
Organon (the Netherlands; unit of Akzo Nobel) |
Deal to identify and develop compounds in three undisclosed therapeutic areas |
Organon acquired an equity interest in HUYA, which identifies Chinese drug candidates for commercialization in Western markets; terms were not disclosed (1/9) |
iCo |
Cambridge Antibody Technology (unit of AstraZeneca plc; UK) |
iCo got worldwide rights to CAT-213, a human monoclonal antibody previously developed by CAT for allergy disorders |
CAT is entitled to an up-front fee along with potential milestone and royalty payments; iCo initially plans to develop the product in ocular allergies (1/8) |
Idera |
Merck & Co. Inc. |
Deal to incorporate Idera's Toll-like receptor agonists into vaccines Merck is developing in oncology, infectious diseases and Alzheimer's disease |
Idera gets $20M up front and a $10M equity investment at $5.50 per share; milestones up to $165M could be paid if vaccines are developed in all three fields; $260M more in milestones could be paid for other successful development (12/11) |
Immunicon |
Eisai Co. Ltd. (Japan) |
Research deal to develop biomarkers for certain proteins |
The markers would be used for targeted therapies or to monitor treatment efficacy; terms of the deal were not disclosed (12/7) |
Immunicon |
Novartis Pharmaceutical Corp. (subsidiary of Novartis AG; Switzerland) |
Collaboration to develop a family of biomarkers associated with circulating tumor cells that might be useful in determining the efficacy of certain cancer therapies in development by Novartis |
A second agreement governs laboratory services that Immunicon will perform in connection with various cancer drug development programs; financial terms were not disclosed (1/29) |
ImmunoGen |
Sanofi Aventis Group (France) |
Sanofi got an option to gain expanded access to Tumor-Activated Prodrug antibody technology |
The deal that began in 2003 was extended into 2008, and increases the number of targets available for study; ImmunoGen got $0.5M for the option, and remains entitled to additional payments (12/26) |
Inhibitex Inc. |
3M Health Care |
Deal to develop various diagnostic products using Inhibitex's MSCRAMM protein platform |
Inhibitex is entitled to license fees, R&D support and potential milestone and royalty payments; 3M also licensed rights to use additional MSCRAMM protein targets (1/4) |
Kamada Ltd. |
PARI Aerosol Research Institute Institute (Germany) |
Deal to develop an inhaled alpha-1 antitrypsin product for treating AAT deficiency |
Phase I trials were starting of the product combining Kamada's liquid drug candidate and PARI's eFlow device; terms of the deal were not disclosed (11/20) |
KineMed Inc.* |
Merck & Co. Inc. |
Deal under which KineMed will measure the modulation of targeted metabolic pathways in Merck Phase I trials |
The deal follows a feasibility study using KineMed's KineMarker technology; terms of the deal were not disclosed (11/16) |
Kosan |
Pfizer Inc. |
Deal to develop Kosan's motilin agonist program, including the lead preclinical candidate, KOS-2187, which targets gastrointestinal diseases |
Kosan gets $12.5M up front, and up to $250M in milestones ($72.5M in development milestones) related to KOS-2187 for one indication, as well as royalties on sales; other indications or compounds would trigger additional payments (12/19) |
LifeSpan |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Multiyear agreement for a subscription to LifeSpan's DrugTarget Database |
Roche gained access to all the features of the CNS subset of the database (1/30) |
Lipoxen plc |
Baxter International Inc. |
Exclusive deal to develop longer-acting forms of blood-clotting factors |
The deal follows a 12-month evaluation period; Lipoxen get $1M, as well as milestone payments of up to $75M, plus royalties on resulting sales (12/15) |
Medivir AB |
Jiangsu Hengrui Medicine Co. (China) |
They extended deal from 2003 focused on developing protease inhibitors for chronic obstructive pulmonary disease |
The pact was extended until June 2007; Hengrui would get rights to resulting com- pounds in China; Medivir would retain all other rights (11/20) |
MedImmune |
Japan Tobacco Inc. (Japan) |
MedImmune got rights to develop a monoclonal antibody targeting pathways within the CD28 receptor family |
The target is certain inflammatory diseases; JT gets an up-front payment, and could get milestone and royalty payments; JT retained rights in Japan (12/28) |
MedImmune |
CSL Ltd. (Australia) |
CSL got rights to reverse genetics technology for use in development of seasonal and pandemic influenza vaccines |
MedImmune gets an up-front payment, and could receive royalties on any vaccine stockpiles or other product sales (12/20) |
MedImmune |
BioWa Inc. (unit of Kyowa Hakko Kogyo Co. Ltd.; Japan) |
Deal to develop and market inflammatory disease therapies targeting the interleukin-5 receptor |
The inital focus is on BioWa's BIW-8405 anti- body, which is in Phase I asthma trials; BioWa gets an up-front payment, along with potential milestone payments and royalties; it retained rights in Japan and certain other Asian countries (12/19) |
Metabasis |
Schering-Plough Corp. |
Schering-Plough got worldwide rights to pradefovir, an oral agent in Phase II trials for treating hepatitis B virus |
Valeant licensed pradefovir from Metabasis in 2000; they are entitled to up- front payments from Schering-Plough, as well as milestone and royalty payments (12/13) |
Mirus Bio |
Pfizer Inc. |
Two-year deal to use Mirus' nucleic acid delivery platforms in research applications |
They will use the platforms to investigate and optimize gene silencing methods in animal models, targeting and suppressing genes of interest to Pfizer (1/9) |
Molecular |
Bayer Schering Pharma AG (Germany) |
Molecular Insight acquired Solazed (ZK-BA) |
The company will pay Bayer Schering a licensing fee, regulatory milestones and royalties on future sales; Molecular Insight gains exclusive, worldwide rights to Solazed, which targets melanin, which is overexpressed in 40% of melanoma tumors (1/17) |
Molecular |
Novartis Pharma |
Worldwide, exclusive licensing agreement to develop and sell Onalta, |
Molecular Insight will pay Novartis a licensing fee, plus regulatory milestone payments and royalties (1/24) |
MorphoSys |
Pfizer Inc. |
They extended until 2011 a deal begun in 2003 under which MorphoSys is generating antibodies against targets from Pfizer |
The potential value for MorphoSys in research funding and developmental milestone payments increased to more than $100M; it also got a one-time payment, and would get royalties on sales (12/20) |
MorphoSys |
Boehringer Ingelheim |
BI exercised an option to acquire exclusive rights to a HuCAL antibody against cancer |
MorphoSys is entitled to additional funding under an expansion of a five-year deal they began in 2003 (11/13) |
Neurogen |
Wyeth |
Neurogen acquired all rights to Aplindore, a small molecule partial agonist for the D2 dopamine receptor |
Phase II trials in Parkinson's disease and restless legs syndrome were being planned; Wyeth gets $3M up front, along with potential milestone and royalty payments (11/28) |
OctoPlus NV |
Green Cross |
Green Cross got exclusive rights in Korea to the Phase II drug OP-145 for treating chronic middle ear infection |
OctoPlus gets an up-front payment and retains manufacturing rights; it is eligible to receive milestone payments and royalties on resulting sales (11/22) |
Oscient |
Menarini Group |
Menarini got rights to commercialize the antibiotic Factive in Europe |
Oscient gets an up-front payment, and is eligible to receive regulatory and sales milestone payments; it also will sell product to Menarini (12/4) |
OSI |
Eli Lilly and Co. |
Lilly got exclusive rights to OSI's Glucokinase Activator program, which includes the Phase I diabetes agent PSN010 |
OSI gets $25M up front and up to $360M in development and sales milestones and other payments, plus royalties on any resulting sales (1/5) |
OSI |
Bristol-Myers |
BMS got nonexclusive rights to technology for development of DPIV inhibitors for treating Type II diabetes and related indications |
The license was granted by OSI subsidiary Prosidion; OSI gets an up-front payment, as well as potential milestone and royalty payments (12/14) |
Palatin |
AstraZeneca plc |
A $310M deal to develop small-molecule compounds for obesity and other metabolic disorders |
Palatin gets $10M up front, and is eligible to receive up to $180M in development and regulatory milestones, plus another potential $120M based on sales milestones (1/31) |
PanGenetics |
Schering-Plough |
PanGenetics got rights to an undisclosed preclinical therapeutic antibody |
Schering-Plough has an option to regain rights to the product after initial studies; if exercised, PanGenetics would be eligible to receive more than $50M in up-front and milestones payments (11/30) |
Peptimmune |
Orphan Europe |
Deal to develop a peptide immunotherapy for treating pemphigus vulgaris, an autoimmune skin disease |
Orphan Europe will continue development of a Phase I product from Peptimmune, and would market it in Europe, the Middle East and Africa; terms were not disclosed (11/9) |
Pharmacopeia |
Wyeth |
Deal to develop Pharmacopeia's JAK3 inhibitor program for treating various immunological conditions |
Pharmacopeia retains rights to develop topical products for dermatological and ocular diseases; Wyeth has all other rights; Pharmacopeia gets $5M up front and up to $9M in research funding over three years, as well as up to $175M in milestone payments and double-digit royalties on resulting sales (12/4) |
Pharmion |
Nippon Shinyaku |
Shinyaku got rights in Japan to Vidaza, which is approved in the U.S. for treating myelodysplastic syndromes |
Shinyaku will fund and conduct studies required for approval in Japan; Pharmion is entitled to milestone and royalty payments in the deal (11/21) |
Pharminox |
Schering-Plough |
Pharminox will provide medicinal chemistry services in a deal to discover small- molecule anticancer therapies |
Pharminox gets two years of funding, and would be eligible to receive milestone and royalty payments on resulting products; R&D and milestone payments could exceed $40M (12/11) |
ProMetic |
Novartis Vaccines |
Deal to develop a synthetic-ligand affinity adsorbent for the purification of a recombinant protein vaccine |
PBL's subsidiary in the UK will screen its chemical combinatorial libraries for suit- able ligands; terms of the deal were not disclosed (12/4) |
Protherics |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Protherics acquired rights to Digitalis Antidot, a treatment for digoxin toxicity |
Protherics intends to replace the product in the market with its own digitalis antidote, DigiFab; terms included a "small" payment to Roche (11/27) |
pSivida Ltd. |
Faber Research LLC |
Deal to develop pSivida's drug delivery technologies for infectious diseases and diseases of the ear |
Faber had paid $1M for an option to the technology; pSivida is entitled to milestone and royalty payments; Faber's rights are exclusive in diseases of the ear, and in malaria, HIV/AIDS, influenza, tuberculosis and osteomyelitis (1/9) |
pSivida Ltd. |
Undisclosed company |
The pharmaceutical company got rights to negotiate an exclusive license to pSivida's drug delivery technologies |
The unnamed firm is paying $1M for the three-month option and to fund a preclinical study (12/26) |
PsychoGenics |
Eli Lilly and Co. |
PsychoGenics will evaluate drug candidates from Lilly for the treatment of neuropsychiatric disorders |
Either company could exclusively develop resulting candidates; the other would be entitled to milestone and royalty payments (12/19) |
PTC |
Pfizer Inc. |
Exclusive deal to use PTC's GEMS gene expression technology to discover drugs against various targets |
PTC gets $10M up front, a $10M equity investment and research funding; the deal could include up to 10 targets; PTC could earn milestones of up to $121M per target; it also would get royalties on resulting sales (1/8) |
Raven |
Wyeth Pharmaceuticals |
Deal to develop monoclonal antibodies from Raven against an undisclosed target |
Wyeth has an option to exclusively license resulting therapies; Raven gets an up-front payment, along with potential milestone and royalty payments (1/4) |
Sangamo |
Edwards Lifesciences Corp. |
Sangamo is acquiring Edwards' angiogenesis program; they began a collaboration in that area in 2000 |
Edwards gets 1M Sangamo shares, which were valued at $7.45M; it also would get royalties on certain resulting sales (12/4) |
Scynexis |
Merck & Co. Inc. |
Multiyear research deal to discover and develop oncology compounds |
Scynexis will produce compound libraries and provide lead optimization in the deal, terms of which were not disclosed (12/6) |
Sirion |
Laboratoires Thea (France) |
Exclusive licensing agreement for the U.S. rights to develop and market a topical ophthalmic |
The product is marketed by Thea in Europe under the brand name Virgan (1/17) |
SuperGen |
Mayne Pharma Ltd. (Australia) |
Mayne is acquiring the remaining worldwide rights to the hairy-cell leukemia |
Mayne paid $34M in August 2006 for the North American rights; it will pay up to $8M more for the remaining rights (11/27) |
Symphogen |
Meiji Seika Kaisha Ltd. (Japan) |
Deal to develop a fully human recombinant polyclonal antibody product targeting an undisclosed bacterial pathogen |
They will use Symphogen's antibody discovery technology in the effort; Symphogen gets an up-front fee and potential milestone and royalty payments; it also retained certain co-development rights (12/11) |
Synosis |
F. Hoffmann- La Roche Ltd. (Switzerland) |
Deal to develop five central nervous system compounds that Synosis is acquiring from Roche, including four Phase I molecules |
Roche retained the right to opt-in to two of the programs; Synosis has full rights to the other three; the agents target a range of CNS disorders; terms of the deal were not disclosed (1/3) |
TechnoVax |
Wyeth |
TechnoVax got rights related to virus-like particle vaccine technology |
Wyeth is entitled to an up-front payment, annual payments and potential milestone and royalty payments; it also will get an equity stake in TechnoVax (12/11) |
Viragen Inc. |
Orphan Australia Pty. Ltd. (Australia) |
Orphan got rights to the alpha-interferon product Multiferon in Australia and New Zealand |
Orphan's initial focus will be in melanoma; Viragen gets an up-front and potential milestone payments (12/28) |
VistaGen |
Sanwa Kagaku Kenkyusho Co. Ltd. (Japan) |
They renewed a deal to develop VistaGen's stem cell technologies for treating diabetes |
VistaGen is entitled to additional research funding and potential milestone payments under the renewal; it would get royalties on resulting sales; VistaGen also retained certain commercial rights (11/30) |
Xenon |
F. Hoffmann- La Roche Ltd. (Switzerland) |
Deal to develop protein therapeutics targeting hemojuvelin as a treatment for anemia of inflammation |
Xenon got a $7M equity investment, and could get up to $44M in milestones for the first product; it would get royalties on sales, and retained a co-promotion option in Canada (12/7) |
U.S. Genomics* |
Quest Diagnostics Inc. |
Worldwide license agreement for rights to develop an advanced screening method |
Quest plans to develop an automated testing process; terms were not disclosed (1/22) |
YM |
TTY Biopharm Ltd. (Taiwan) |
Deal to expand development of YM's tesmilifene into hepatic cancer |
TTY will fund development costs and provide to YM undisclosed up-front, milestone and royalty payments (12/21) |
| Notes: | |||
| # The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
| * Private companies are indicated with an asterisk; ** Denotes the date the item ran in BioWorld International. | |||
| Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
| AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; HSE = Helsinki Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; SWX = Swiss Stock Exchange; TSX = Toronto Stock Exchange. | |||
